While shares of Columbia/HCA Healthcare Corp took a beating Monday following a federal probe and media reports about its billing practices , industry analysts continued to support the stock .
The stock has dropped sharply in the past two weeks as news of the federal probe of its El Paso operations surfaced .

Chiarelli said he continues to rate the stock as a buy .
Investor concerns also have been fueled by a recent New York Times report concerning the Nashville , Tenn.-based company's Medicare coding practices and physician ownership in certain of its hospitals .
Analysts cautioned that the New York Times used its own methodology , which has not been verified by others in the healthcare industry , as the basis of its article .

Analysts expect Columbia/HCA's stock to continue to face near-term pressure but said the company will remain a market leader over the long-term .
USA : Columbia/HCA still seen as solid buy despite probe .

Columbia/HCA still seen as solid buy despite probe .
"_ We_ 're not in a hurry to sell the stock .
The stock will rebound , but I expect continued negative commentary to pressure the stock for the near-term , _" John Hindelong , an analyst with Donaldson , Lufkin & Jenrette .

